Bimekizumab - UCB Pharma

Drug Profile

Bimekizumab - UCB Pharma

Alternative Names: CDP-4940; UCB-4940

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 28 Nov 2017 UCB initiates enrolment in a phase II extension trial for Ankylosing spondylitis in USA (SC) (NCT03355573)
  • 28 Nov 2017 UCB initiates enrolment in a phase II extension trial for Ankylosing spondylitis in Hungary (SC) (EudraCT2017-001002-15)
  • 22 Nov 2017 Phase-II clinical trials in Psoriatic arthritis (In the elderly, In adults) in USA, Germany (SC) (NCT03347110) (EudraCT2017-001003-74)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top